Accure Therapeutics Revenue and Competitors

Barcelona, Spain

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Accure Therapeutics's estimated annual revenue is currently $1.1M per year.(i)
  • Accure Therapeutics's estimated revenue per employee is $84,000

Employee Data

  • Accure Therapeutics has 13 Employees.(i)
  • Accure Therapeutics grew their employee count by 0% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M130%N/AN/A
Add Company

What Is Accure Therapeutics?

A new medicine R&D engine (R&D pharma company) operated by an experienced team dedicated to the discovery and development of new medicines to treat patient suffering from severe diseases of the central nervous system. Accure Therapeutics focuses on neurons that suffer a dysfunction, and on the glial environment that supports them, in an attempt to impede their degeneration and death. We work to find new medicines that correct the pathological changes that are responsible for the disease, and that produce beneficial outcomes (i.e. Disease Modifying Therapies). We specialize in developing drugs that promote neuroprotection and neurorepair by integrating the latest advances in neurobiology with state-of-the-art clinical research. We have currently built up a drug candidate portfolio that focuses on four areas: Optic Neuritis, Multiple Sclerosis, Parkinson's Disease and Epilepsy.

keywords:N/A

N/A

Total Funding

13

Number of Employees

$1.1M

Revenue (est)

0%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Accure Therapeutics News

2022-03-22 - Oculis Strengthens Leading Ophthalmology Pipeline by In ...

Accure Therapeutics is a private translational neuroscience R&D company. Based in Barcelona (Spain), it was launched in 2020 with a Series A...

2022-03-22 - Oculis and Accure Therapeutics Form Licensing Agreement ...

Oculis, a global ophthalmology company, announced on March 2, 2022 that it has formed a licensing agreement with Accure Therapeutics,...

2022-03-22 - Oculis adds to ophthalmology pipeline with Accure deal

Privately-held Swiss ophthalmology company Oculis and private Spanish translational neuroscience R&D firm Accure Therapeutics have announced...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$2M130%N/A
#2
$1.9M13-19%N/A
#3
$1.6M13-13%N/A
#4
$2.4M13-24%N/A
#5
$1.4M138%N/A